Skip to main content

Table 5 Overall survival in the LV and HV cohorts according to time of metastatic disease presentation

From: Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

LV cohort (n = 244)

N. patients

(%)

N. deaths

(%)

OS (%)

(SE)

p-value*

Median OS, months (95% CI)

HR (95% CI)

p-value°

PLT

DN

157 (64.3)

87 (35.7)

59 (60.2)

39 (39.8)

32.4 (8.9)

16.3 (9.1)

0.11

61.9 (50.0–73.8)

47.9 (43.4–52.5)

1 (ref)

1.39 (0.93–2.10)

0.11

HV cohort

(n = 173)

N. patients

(%)

N. deaths

(%)

OS (%)

(SE)

p-value*

Median OS

months (95% CI)

HR (95% CI)

p-value°

PLT

DN

64 (37.0)

109 (63.0)

40 (37.0)

68 (63.0)

20.9 (6.6)

9.9 (5.4)

0.71

27.5 (21.4–33.6)

27.8 (19.8–35.8)

1 (ref)

0.93 (0.63–1.37)

0.71

  1. CI confidence interval, DN de-novo, HR hazard ratio, HV high volume, LV low volume, OS overall survival, PLT prior local therapy, SE standard error
  2. *p-value from log-rank test; °p-value from univariate Cox regression analysis